Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic
- 6 March 2017
- journal article
- review article
- Published by Taylor & Francis in Infectious Diseases
- Vol. 49 (7) , 483-492
Abstract
Dalbavancin, a recently approved glycopeptide antibiotic, whose disposition is not affected by renal function as compared to vancomycin is used to treat serious infections caused by Staphylococci and Streptococci including multiple drug-resistant strains. Although reviews of the pharmacodynamic and clinical efficacy of dalbavancin have been published, a comprehensive overview of the pharmacokinetic properties including distribution and disposition in animals and humans has not been published. The aim of this review is to summarize the pharmacokinetics of dalbavancin, which justifies the intravenous dosing regimens and to provide considerations and perspectives with regard to dosing strategies. It is concluded that dalbavancin, despite high protein binding offers pharmacokinetic benefits such as good tissue penetration and long half-life. Dalbavancin may be a drug of choice and replace more resource demanding intravenous drugs to treat serious infections in a hospital setting.Keywords
This publication has 36 references indexed in Scilit:
- Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?International Journal of Antimicrobial Agents, 2013
- New LipoglycopeptidesDrugs, 2010
- Dalbavancin: A new lipoglycopeptide antibioticAmerican Journal of Health-System Pharmacy, 2008
- Distribution of Radioactivity in Bone and Related Structures following Administration of [ 14 C]Dalbavancin to New Zealand White RabbitsAntimicrobial Agents and Chemotherapy, 2007
- Tissue Penetration of Telavancin after Intravenous Administration in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2006
- Safety and efficacy of glycopeptide antibioticsJournal of Antimicrobial Chemotherapy, 2005
- Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptideJournal of Antimicrobial Chemotherapy, 2005
- Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram DoseAntimicrobial Agents and Chemotherapy, 2005
- Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004
- Clinical Pharmacokinetics of TeicoplaninClinical Pharmacokinetics, 2000